Coya Therapeutics, Inc. COYA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 48.96% | -2.64% | 197,900.00% | -- | -95.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.96% | -2.64% | 197,900.00% | -- | -95.22% |
| Cost of Revenue | 37.33% | -21.43% | 155.01% | 31.16% | -19.78% |
| Gross Profit | -36.79% | 22.41% | 49.34% | 129.11% | -206.73% |
| SG&A Expenses | -22.44% | 39.36% | 52.94% | 15.22% | 39.25% |
| Depreciation & Amortization | -58.82% | -58.82% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.81% | -0.67% | 101.30% | 23.16% | -1.25% |
| Operating Income | -9.83% | 0.61% | -4.34% | 56.93% | -98.22% |
| Income Before Tax | -8.91% | 1.37% | -56.91% | 47.39% | -110.78% |
| Income Tax Expenses | -- | -- | 100.43% | -- | -- |
| Earnings from Continuing Operations | -8.91% | 1.37% | -95.78% | 47.39% | -110.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.91% | 1.37% | -95.78% | 47.39% | -110.78% |
| EBIT | -9.83% | 0.61% | -4.34% | 56.93% | -98.22% |
| EBITDA | -9.91% | 0.56% | -4.34% | 57.01% | -98.42% |
| EPS Basic | 22.34% | 27.16% | -91.25% | 52.16% | -87.93% |
| Normalized Basic EPS | 22.39% | 27.28% | -5.69% | 63.78% | -87.95% |
| EPS Diluted | 22.34% | 27.16% | -91.25% | 52.16% | -87.93% |
| Normalized Diluted EPS | 22.39% | 27.28% | -5.69% | 63.78% | -87.95% |
| Average Basic Shares Outstanding | 40.25% | 35.43% | 2.36% | 9.93% | 12.13% |
| Average Diluted Shares Outstanding | 40.25% | 35.43% | 2.36% | 9.93% | 12.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |